AmerisourceBergen Corp. won’t have to worry about violating federal antitrust law as it collaborates with other healthcare distributors and US government agencies on a pharmaceutical supply chain “control tower tool” to deliver medicines needed in COVID-19 hot spots around the nation, thanks to a 20 April business review letter from the US Department of Justice.
The letter protects AmerisourceBergen from antitrust risks as it works for free with other healthcare distributors to help the government distribute hydroxychloroquine that drug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?